TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+5.28%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.69B
AUM Growth
+$2.69B
(+12%)
Cap. Flow
+$181M
Cap. Flow
% of AUM
6.73%
Top 10 Holdings %
Top 10 Hldgs %
49.42%
Holding
121
New
19
Increased
15
Reduced
14
Closed
13
Top Buys
| 1 |
Viatris
VTRS
|
$56.1M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$53.5M |
| 3 |
Johnson & Johnson
JNJ
|
$43.9M |
| 4 |
Alkermes
ALKS
|
$28.8M |
| 5 |
Teva Pharmaceuticals
TEVA
|
$23M |
Top Sells
| 1 |
AbbVie
ABBV
|
$71.2M |
| 2 |
Gilead Sciences
GILD
|
$23.4M |
| 3 |
Perrigo
PRGO
|
$21.6M |
| 4 |
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
|
$19.4M |
| 5 |
Heron Therapeutics
HRTX
|
$13.6M |
Sector Composition
| 1 | Healthcare | 86.5% |
| 2 | Real Estate | 3.17% |
| 3 | Financials | 1.57% |
| 4 | Technology | 0.04% |
| 5 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Gilead Sciences
GILD
$140B
| $243M | 8.81% | 2,079,731 -200,000 | -9% | -$23.4M |
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $223M | 8.08% | 1,929,234 -65,600 | -3% | -$7.59M |
|
3
Biogen
BIIB
$19.4B
| $143M | 5.16% | 353,233 +13,750 | +4% | +$5.55M |
|
|
4
Viatris
VTRS
$12.3B
| $125M | 4.51% | 1,837,005 +826,900 | +82% | +$56.1M |
|
|
5
Vertex Pharmaceuticals
VRTX
$100B
| $111M | 4.01% | 897,903 +433,659 | +93% | +$53.5M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $106M | 3.82% | 584,305 +82,000 | +16% | +$14.8M |
|
|
AGN
7
DELISTED
Allergan plc
AGN
| $104M | 3.77% | 343,686 -18,000 | -5% | -$5.46M |
|
8
Regeneron Pharmaceuticals
REGN
$61.5B
| $95.5M | 3.45% | 187,166 | – | – |
|
9
Incyte
INCY
$16.5B
| $91.8M | 3.32% | 880,461 -56,000 | -6% | -$5.84M |
|
|
10
Johnson & Johnson
JNJ
$427B
| $86.2M | 3.12% | 884,612 +450,000 | +104% | +$43.9M |
|
|
11
Teva Pharmaceuticals
TEVA
$21.1B
| $82M | 2.97% | 1,387,594 +390,000 | +39% | +$23M |
|
12
Amgen
AMGN
$155B
| $76.3M | 2.76% | 497,280 +145,501 | +41% | +$22.3M |
|
13
BioMarin Pharmaceuticals
BMRN
$11.2B
| $73.2M | 2.65% | 534,977 | – | – |
|
|
14
Alkermes
ALKS
$4.78B
| $66.6M | 2.41% | 1,035,470 +447,000 | +76% | +$28.8M |
|
15
Pfizer
PFE
$141B
| $54.9M | 1.99% | 1,638,241 | – | – |
|
16
Illumina
ILMN
$15.8B
| $50.1M | 1.81% | 229,641 +96,400 | +72% | +$21M |
|
|
AET
17
DELISTED
Aetna Inc
AET
| $42.3M | 1.53% | 331,931 | – | – |
|
|
AKRX
18
DELISTED
Akorn, Inc.
AKRX
| $37.1M | 1.34% | 849,482 | – | – |
|
19
Bristol-Myers Squibb
BMY
$96B
| $35.6M | 1.29% | 535,240 | – | – |
|
|
CTRX
20
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
| $26.5M | 0.96% | 433,600 | – | – |
|
|
ENDP
21
DELISTED
Endo International plc
ENDP
| $26M | 0.94% | 325,873 +74,100 | +29% | +$5.9M |
|
22
Molina Healthcare
MOH
$9.8B
| $24.5M | 0.88% | 347,901 | – | – |
|
|
MDRX
23
DELISTED
Veradigm Inc. Common Stock
MDRX
| $24.3M | 0.88% | 1,778,200 | – | – |
|
|
RCPT
24
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $23.7M | 0.86% | 124,800 | – | – |
|
|
ACOR
25
DELISTED
Acorda Therapeutics, Inc.
ACOR
| $22.7M | 0.82% | 680,862 | – | – |
|